Endothelial Dysfunction: The First Thing That Goes Wrong

Before there is plaque, before there is a blockage visible on any scan, there is a single cell layer that stops doing its job. The endothelium, the monolayer lining every blood vessel in contact with circulating blood, is not passive scaffolding. It is an active endocrine and signaling organ that produces the molecules that keep vessels relaxed, resist platelet adhesion, and suppress the inflammatory sequence that produces atherosclerosis. When it stops working well, the downstream consequences accumulate over years before any standard cardiac test identifies them. In women, the biology that supports this layer is shaped by reproductive hormones across the full life course in ways that have direct clinical meaning.

The Mechanism

Every blood vessel is lined by a continuous sheet of endothelial cells in direct contact with flowing blood. These cells produce nitric oxide (NO) via the enzyme endothelial nitric oxide synthase (eNOS), and that nitric oxide performs multiple functions simultaneously: it relaxes the smooth muscle cells beneath the endothelium, producing vasodilation; it reduces platelet adhesion and aggregation, lowering thrombotic risk; it suppresses the expression of cell adhesion molecules that would allow circulating inflammatory cells to bind to the vessel wall and initiate the inflammatory cascade; and it limits the retention of LDL particles within the vessel wall, blunting the earliest step in atherogenesis.

Endothelial dysfunction is the term for the state in which this system underperforms. NO production falls, oxidative stress within the vessel wall increases, and the endothelium shifts from an anti-inflammatory, anti-atherogenic state toward a pro-inflammatory one. The vessel becomes a site where inflammation can be initiated and sustained, where platelet adhesion increases, and where LDL oxidation and retention proceed more readily. All of this occurs before any structural plaque is detectable by imaging.

This is the key temporal point for understanding why endothelial dysfunction matters specifically in women with normal cardiac tests: the dysfunction is real, measurable, and clinically consequential at a stage when coronary CT angiography shows no obstructive disease, when a stress test is negative, and when a coronary calcium score is zero. The standard cardiac test panel measures downstream events. Endothelial dysfunction is upstream of those events. A woman can have severely impaired endothelial function and a completely normal standard cardiac workup simultaneously, and that combination does not mean she has no cardiovascular disease; it means her disease is in its earliest detectable stage.

How does testing reveal this dysfunction when standard tests do not? Flow-mediated dilation (FMD) of the brachial artery is the research standard. A blood pressure cuff inflated above the elbow occludes forearm flow, creating upstream reactive hyperemia when released. Under normal conditions, the resulting increase in shear stress triggers endothelium-dependent vasodilation mediated by NO release. The magnitude of brachial artery dilation, measured by ultrasound, reflects systemic endothelial function. Impaired FMD, typically defined as dilation less than 5 to 7 percent depending on the protocol used, predicts cardiovascular events independently of traditional risk factors in prospective studies. It captures something that the Framingham risk score does not.

FMD is a specialized research and clinical tool, not a standard clinical measurement. But the data it generates establish the timeline of disease: endothelial dysfunction is measurable in people who have no symptoms, no plaque on imaging, and no traditional risk factors at threshold values. It is the earliest step in the sequence.

Coronary function testing goes further: by measuring endothelium-dependent coronary vasodilation directly in the coronary circulation during catheterization, it assesses the endothelial status of the vessels that actually supply the heart. Acetylcholine infused into the coronary artery normally produces vasodilation through NO release; in a vessel with endothelial dysfunction, it produces vasoconstriction instead. This reversal is the diagnostic criterion for coronary endothelial dysfunction in invasive testing.

What the Evidence Shows

The evidence connecting impaired FMD to future cardiovascular events is extensive and has been established across multiple large prospective cohorts. A 2012 meta-analysis by Inaba and colleagues in the Journal of the American College of Cardiology pooled data from 5,547 participants across 23 studies and found that impaired FMD predicted cardiovascular events independently of Framingham risk score, with a hazard ratio of approximately 2.0 per one standard deviation decrease in FMD. This was a robust effect across diverse study populations and measurement protocols.

The sex-specific FMD literature has established that women have higher baseline FMD than age-matched men during the premenopausal years, and that this advantage attenuates across the menopause transition. A 2014 study by Moreau and colleagues in Arteriosclerosis, Thrombosis, and Vascular Biology compared FMD across age groups and menopausal status and found that FMD declined significantly in perimenopause and early postmenopause, tracking the fall in estradiol levels, and that postmenopausal women had FMD values similar to age-matched men despite having started with higher values in younger adulthood. This is a prospective loss of cardiovascular protection that no conventional risk score captures.

The estrogen-eNOS connection is mechanistically well established. Estrogen binds to estrogen receptor alpha (ERa) on endothelial cells, and through both the classical genomic pathway (transcription of eNOS mRNA over hours) and the rapid non-genomic pathway (phosphorylation of eNOS via PI3K-Akt signaling within minutes), it increases NO production. The consequence is that baseline endothelial vasodilatory capacity in premenopausal women is supported by estrogen in a way that is absent in men and in postmenopausal women. This is part of the mechanistic basis for why premenopausal women have substantially lower coronary event rates than men of equivalent age, a sex-differential that the Framingham cohort established and subsequent studies have consistently confirmed.

The WISE study (Women’s Ischemia Syndrome Evaluation), conducted across four American clinical centers and enrolling women referred for coronary angiography for suspected ischemia, documented the downstream cardiovascular consequences of endothelial dysfunction in a population where standard angiography was frequently normal. Women in WISE with coronary endothelial dysfunction on invasive testing, defined by the vasoconstriction response to acetylcholine, had a significantly elevated rate of major adverse cardiac events over a median follow-up of five years compared with women with normal coronary endothelial responses, despite having angiographically non-obstructive coronary arteries. WISE established that endothelial dysfunction in women without obstructive CAD carries a prognosis that is not benign.

Reproductive history is now recognized as an endothelial history. Conditions that reflect endothelial dysfunction during pregnancy, including preeclampsia, gestational hypertension, and placental abruption, are associated with elevated long-term cardiovascular risk. A 2019 review by Maas and colleagues in the European Heart Journal synthesized data from multiple cohort studies and found that women with a history of preeclampsia had a two- to fourfold higher risk of later hypertension and a 1.5- to twofold higher risk of coronary artery disease compared with women with uncomplicated pregnancies. These are not separate phenomena from endothelial dysfunction: the placental endothelium and the systemic coronary endothelium share biology, and a pregnancy that unmasks endothelial failure is identifying a woman whose vascular biology warrants long-term attention.

The modifiable risk factors that damage the endothelium are well characterized. High blood pressure applies abnormal shear stress to the vessel wall, activating inflammatory pathways that downregulate eNOS and increase reactive oxygen species. Oxidized LDL impairs eNOS activity directly and promotes the expression of adhesion molecules. Smoking introduces reactive oxygen species that degrade NO faster than it can be produced. Elevated blood glucose promotes glycation of endothelial proteins and activates protein kinase C, increasing oxidative stress. Chronic low-grade inflammation, as in metabolic syndrome or visceral obesity, sustains a state in which inflammatory cytokines consume NO and promote endothelial activation. Physical inactivity removes the shear stress stimulus that is among the most potent physiological drivers of eNOS expression; sedentary vessels are endothelially deprived vessels.

The interaction among these factors is not simply additive. Two or three moderate-magnitude risk factors together damage the endothelium more than the sum of their individual effects would suggest, because they converge on a common mechanism: reduction of NO bioavailability through both decreased production and increased degradation.

Pregnancy Complications as Endothelial Stress Tests

The analogy between a cardiac stress test and a complicated pregnancy is instructive and clinically underappreciated. A cardiac stress test imposes hemodynamic demand that reveals coronary disease not apparent at rest — the diseased artery cannot deliver adequate flow under load, and ischemia becomes visible. A complicated pregnancy works similarly at the vascular level: the placental circulation imposes substantial demands on maternal endothelial function, and women whose endothelium cannot meet those demands manifest complications that reveal pre-existing vascular vulnerability.

Preeclampsia provides the clearest example. Successful placentation requires the maternal spiral arteries to undergo profound remodeling — they must dilate substantially to supply the placenta’s blood demand. This remodeling is driven by trophoblast invasion and depends on normal maternal vascular endothelial function. When endothelial function is impaired, by pre-existing hypertension, insulin resistance, obesity, autoimmune factors, or underlying vascular biology, the remodeling is incomplete, the placenta is under-perfused, and the ischemic placenta releases sFlt-1 (soluble fms-like tyrosine kinase 1) that impairs circulating VEGF and PlGF (placental growth factor). The consequence is systemic maternal endothelial dysfunction: hypertension, proteinuria, and in severe cases, neurological and hepatic involvement.

The cardiovascular implication is that women who develop preeclampsia do not have a normal endothelium that was transiently overwhelmed by a difficult pregnancy. They have an endothelium that was already compromised before the pregnancy, and that the pregnancy unmasked. Benschop and colleagues, in a study published in Hypertension in 2017, measured brachial FMD in women an average of 7 years after a preeclamptic pregnancy and compared them to parous controls matched for age and blood pressure. FMD was significantly lower in the preeclampsia group, confirming persistent endothelial dysfunction years after the obstetric event resolved. 4 / Promising

Gestational hypertension without proteinuria, placental abruption, and fetal growth restriction each carry similar though somewhat smaller signals of underlying maternal vascular vulnerability. In each case, the obstetric complication is not the cause of future cardiovascular risk — it is a revelatory event that identifies women who already carry higher endothelial vulnerability than their pre-pregnancy risk profile suggested.

The practical clinical implication is that documenting adverse pregnancy outcomes in a woman’s cardiovascular record is not a historical detail. It is active prognostic information. A woman who developed preeclampsia at age 28 and is now 42 has been carrying an endothelial vulnerability signal for over a decade. Incorporating that signal into her current cardiovascular risk assessment — rather than leaving it in an obstetric record that cardiologists rarely see — changes the clinical picture for preventive intervention.

What to Do This Week

1. Treat the four modifiable drivers with specific targets, not vague goals. Blood pressure below 130/80 mmHg (per the 2017 ACC/AHA guidelines), LDL at the level appropriate for your calculated cardiovascular risk, HbA1c below 7 percent in diabetes, and complete smoking cessation each address endothelial damage through distinct mechanisms. Every one of them matters independently; together they interact beyond simple addition.

2. Start or increase structured aerobic exercise. Exercise is not one option among several for endothelial function; the FMD literature consistently identifies aerobic training as the most robustly effective intervention. Thirty to 45 minutes of moderate-intensity aerobic activity most days of the week is the dose with the strongest evidence. This improves shear stress across the coronary endothelium in ways that pharmacological agents do not replicate.

3. If you have a history of a pregnancy complication, specifically preeclampsia, gestational hypertension, or placental abruption, make sure that history is explicitly documented in your cardiovascular risk file with your primary care physician and cardiologist. The 2019 ESC guidelines on cardiovascular disease prevention include adverse pregnancy outcomes as a risk modifier. A clinician who does not know about a preeclampsia history from 15 years ago cannot apply it to your current risk assessment.

4. If you have had recurrent chest symptoms with non-obstructive coronary imaging and have not had invasive coronary function testing, ask specifically whether that testing, including acetylcholine provocation to assess coronary endothelial response, is appropriate for your situation. Coronary endothelial dysfunction is diagnosable, and the WISE data establish that its presence predicts events even in women with normal-appearing arteries on angiography.

5. If you are in perimenopause or early postmenopause and have two or more modifiable cardiovascular risk factors, request a formal cardiovascular risk assessment that goes beyond a basic lipid panel. A lifetime risk calculation, assessment for subclinical coronary artery disease with coronary calcium scoring if appropriate, and explicit discussion of the endothelial transition at menopause are all clinically grounded at this stage.

The endothelium is where cardiovascular disease begins, and in women its biology is regulated by a hormonal system that changes substantially across the reproductive life and fails at menopause. This is not separate from the standard cardiovascular risk story; it is a layer within it that the standard risk models do not adequately capture. Addressing modifiable inputs early, before the vascular dysfunction becomes structural disease visible on imaging, is the intervention that the normal-test-normal-result framework consistently fails to offer.